| dc.description.abstract | Background: Meniran (Phyllanthus niruri L.) increases the immune system in the
body. The active compound that contained meniran is a flavonoid, which has
immunostimulant activity. Meniran extract in SNEDDS (Self-Nanoemulsifying
Drug Delivery System) could provide an optimal and stable pharmacological effect.
Purpose: This study examined the immunostimulant activity of SNEDDS of
meniran in vitro by determining the phagocytosis activity of RAW 264.7 cells and
measuring the levels of nitric oxide production against latex.
Methods: The research was conducted in vitro, which determined the phagocytosis
activity and production of nitric oxide levels of RAW 264.7 cells. The samples
consist of meniran extract group, a meniran SNEDDS group, a meniran base group,
a market product of meniran group, and a medium control group. Every group
sample consists of four concentration tests (50, 25, 12.5, and 6.25 g/mL). The
phagocytosis activity was observed under a microscope at 40x magnification to get
the phagocytosis index and phagocytic capacity. The nitric oxide production was
analyzed on a microplate reader to obtain absorbance.
Results: The phagocytosis activity test found that RAW 264.7 cells were more
active when given treatment with meniran SNEDDS, especially at a concentration
of 50 g/mL. It was confirmed by the phagocytosis index (0.51 + 0.03) and the total
phagocytosis capacity (52.5 ± 5.90). Likewise, in terms of the production of nitric
oxide, all concentrations of the meniran SNEDDS test (50, 25, 12.5, and 6.25 g/mL)
reached the highest percentage enhancement of NO of 91.283%, 75.000%,
66.595%, and, 58.980%.
Conclusion: Meniran SNEDDS had a higher immunostimulant activity than the
meniran extract, and market product of meniran extract that increase the
phagocytosis activity and stimulates nitric oxide production in the RAW 264.7 cell. | en_US |
